Adjuvant systemic therapy for breast cancer: An overview

Virginia G. Kaklamani, William J. Gradishar

Resultado de la investigación: Chapter


A recommendation for adjuvant systemic therapy is commonly made to women with a diagnosis of early stage breast cancer. The standard adjuvant therapies include chemotherapy, endocrine therapy, and antibody therapy (i.e., trastuzumab). Data from the Surveillance, Epidemiology and End Results (SEER) registries in the United States report a reduction in breast cancer-related mortality of 7.5% since 1973, whereas during the same period, the incidence of invasive breast cancer increased by 25% [1-4]. The improvement in survival for patients with early stage breast cancer coincides with the widespread use of screening mammography and the administration of systemic adjuvant therapy [5-7].

Idioma originalEnglish (US)
Título de la publicación alojadaManagement of Breast Diseases
EditorialSpringer Berlin Heidelberg
Número de páginas31
ISBN (versión impresa)9783540697428
EstadoPublished - dic. 1 2010
Publicado de forma externa

ASJC Scopus subject areas

  • Medicine(all)


Profundice en los temas de investigación de 'Adjuvant systemic therapy for breast cancer: An overview'. En conjunto forman una huella única.

Citar esto